Bulk RNA sequencing data of AB1-HA murine mesothelioma tumors from mice treated with tretinoin and immune checkpoint therapy. Bulk RNA sequencing data of AB1-HA murine mesothelioma tumors from mice treated with tretinoin and immune checkpoint therapy

Bulk RNA sequencing data of AB1-HA murine mesothelioma tumors from mice treated with tretinoin, immune checkpoint therapy or the combination of tretinoin+immune checkpoint therapy. Overall design: Mice bearing AB1-HA were treated with PBS (n=10), tretinoin (n=9), immune checkpoint therapy (anti-CTLA-4+ anti-PD-L1, n=10) or combination tretinoin+immune checkpoint therapy (n=10). 5 mg/kg tretinoin was dosed i.p for 5 doses beginning on day 4. Immune checkpoint therapy commenced on day 7. One tumor was surgically resected on day 9 and stored for RNAseq. For the combination treatment, the remaining tumour was monitored for treatment outcome; responders (R, blue n=6) or non-responders (NR, red, n=4).

本数据集收录经维A酸、免疫检查点疗法，或维A酸联合免疫检查点疗法处理的小鼠体内AB1-HA间皮瘤组织的批量RNA测序（bulk RNA sequencing）数据。实验设计如下：将携带有AB1-HA间皮瘤的小鼠分为四组：磷酸盐缓冲液（PBS）对照组（n=10）、维A酸单药处理组（n=9）、免疫检查点疗法组（抗CTLA-4联合抗PD-L1，n=10），以及维A酸联合免疫检查点疗法组（n=10）。其中维A酸以5 mg/kg的剂量于造模第4日起行腹腔注射（i.p.）给药，共给药5次；免疫检查点疗法于造模第7日启动。于造模第9日手术切除各组小鼠的一处肿瘤组织，冻存以备批量RNA测序。针对联合治疗组小鼠，对其剩余肿瘤持续监测以评估治疗响应结局，并据此分为响应者亚组（R，蓝色标记，n=6）与无响应者亚组（NR，红色标记，n=4）。